RESUMO
BACKGROUND: Physicians spend approximately half of their time on administrative tasks, which is one of the leading causes of physician burnout and decreased work satisfaction. The implementation of natural language processing-assisted clinical documentation tools may provide a solution. OBJECTIVE: This study investigates the impact of a commercially available Dutch digital scribe system on clinical documentation efficiency and quality. METHODS: Medical students with experience in clinical practice and documentation (n=22) created a total of 430 summaries of mock consultations and recorded the time they spent on this task. The consultations were summarized using 3 methods: manual summaries, fully automated summaries, and automated summaries with manual editing. We then randomly reassigned the summaries and evaluated their quality using a modified version of the Physician Documentation Quality Instrument (PDQI-9). We compared the differences between the 3 methods in descriptive statistics, quantitative text metrics (word count and lexical diversity), the PDQI-9, Recall-Oriented Understudy for Gisting Evaluation scores, and BERTScore. RESULTS: The median time for manual summarization was 202 seconds against 186 seconds for editing an automatic summary. Without editing, the automatic summaries attained a poorer PDQI-9 score than manual summaries (median PDQI-9 score 25 vs 31, P<.001, ANOVA test). Automatic summaries were found to have higher word counts but lower lexical diversity than manual summaries (P<.001, independent t test). The study revealed variable impacts on PDQI-9 scores and summarization time across individuals. Generally, students viewed the digital scribe system as a potentially useful tool, noting its ease of use and time-saving potential, though some criticized the summaries for their greater length and rigid structure. CONCLUSIONS: This study highlights the potential of digital scribes in improving clinical documentation processes by offering a first summary draft for physicians to edit, thereby reducing documentation time without compromising the quality of patient records. Furthermore, digital scribes may be more beneficial to some physicians than to others and could play a role in improving the reusability of clinical documentation. Future studies should focus on the impact and quality of such a system when used by physicians in clinical practice.
RESUMO
Background: Tuberculous meningitis (TBM) is the most devastating clinical presentation of infection with Mycobacterium tuberculosis; delayed initiation of effective antituberculosis therapy is associated with poor treatment outcomes. Our objective was to determine the relationship between drug resistance and 10-year mortality among patients with TBM. Methods: We conducted a retrospective cohort study of 324 patients with culture-confirmed TBM, susceptibility results reported for isoniazid and rifampin, and initiation of at least 2 antituberculosis drugs, reported to the tuberculosis registry in New York City between 1 January 1992 and 31 December 2001. Date of death was ascertained by matching the tuberculosis registry with death certificate data for 1992-2012 from the New York Office of Vital Statistics. Human immunodeficiency virus (HIV) status was ascertained by medical records review, matching with the New York City HIV Surveillance registry, and review of cause of death. Results: Among 257 TBM patients without rifampin-resistant isolates, isoniazid resistance was associated with mortality after the first 60 days of treatment when controlling for age and HIV infection (adjusted hazard ratio, 1.94 [95% confidence interval, 1.08-3.94]). Death occurred before completion of antituberculosis therapy in 63 of 67 TBM patients (94%) with rifampin-resistant disease. Conclusions: Among patients with culture-confirmed TBM, we observed rapid early mortality in patients with rifampin-resistant isolates, and an independent association between isoniazid-resistant isolates and death after 60 days of therapy. These findings support the continued evaluation of rapid diagnostic techniques and the empiric addition of second-line drugs for patients with clinically suspected drug-resistant TBM.